Cargando…

Paromomycin for the Treatment of Visceral Leishmaniasis in Sudan: A Randomized, Open-Label, Dose-Finding Study

BACKGROUND: A recent study has shown that treatment of visceral leishmaniasis (VL) with the standard dose of 15 mg/kg/day of paromomycin sulphate (PM) for 21 days was not efficacious in patients in Sudan. We therefore decided to test the efficacy of paramomycin for a longer treatment duration (15 mg...

Descripción completa

Detalles Bibliográficos
Autores principales:	Musa, Ahmed M., Younis, Brima, Fadlalla, Ahmed, Royce, Catherine, Balasegaram, Manica, Wasunna, Monique, Hailu, Asrat, Edwards, Tansy, Omollo, Raymond, Mudawi, Mahmoud, Kokwaro, Gilbert, El-Hassan, Ahmed, Khalil, Eltahir
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2010
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2964291/ https://www.ncbi.nlm.nih.gov/pubmed/21049063 http://dx.doi.org/10.1371/journal.pntd.0000855

Ejemplares similares

Single-dose liposomal amphotericin B (AmBisome(®)) for the treatment of Visceral Leishmaniasis in East Africa: study protocol for a randomized controlled trial
por: Edwards, Tansy, et al.
Publicado: (2011)

Visceral Leishmaniasis: New Health Tools Are Needed
por: Hailu, Asrat, et al.
Publicado: (2005)

Sodium Stibogluconate (SSG) & Paromomycin Combination Compared to SSG for Visceral Leishmaniasis in East Africa: A Randomised Controlled Trial
por: Musa, Ahmed, et al.
Publicado: (2012)

Geographical Variation in the Response of Visceral Leishmaniasis to Paromomycin in East Africa: A Multicentre, Open-Label, Randomized Trial
por: Hailu, Asrat, et al.
Publicado: (2010)

Geographical Variability in Paromomycin Pharmacokinetics Does Not Explain Efficacy Differences between Eastern African and Indian Visceral Leishmaniasis Patients
por: Verrest, Luka, et al.
Publicado: (2021)

The Economic Burden of Visceral Leishmaniasis in Sudan: An Assessment of Provider and Household Costs
por: Meheus, Filip, et al.
Publicado: (2013)

Safety and Effectiveness of Sodium Stibogluconate and Paromomycin Combination for the Treatment of Visceral Leishmaniasis in Eastern Africa: Results from a Pharmacovigilance Programme
por: Kimutai, Robert, et al.
Publicado: (2017)

The Leishmaniasis East Africa Platform (LEAP): strengthening clinical trial capacity in resource-limited countries to deliver new treatments for visceral leishmaniasis
por: Wasunna, Monique, et al.
Publicado: (2016)

Safety and Efficacy of miltefosine alone and in combination with sodium stibogluconate and liposomal amphotericin B for the treatment of primary visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial
por: Omollo, Raymond, et al.
Publicado: (2011)

Safety and Efficacy of Single Dose versus Multiple Doses of AmBisome® for Treatment of Visceral Leishmaniasis in Eastern Africa: A Randomised Trial
por: Khalil, Eltahir A. G., et al.
Publicado: (2014)

Paromomycin and Miltefosine Combination as an Alternative to Treat Patients With Visceral Leishmaniasis in Eastern Africa: A Randomized, Controlled, Multicountry Trial
por: Musa, Ahmed M, et al.
Publicado: (2022)

Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic study
por: Dorlo, Thomas P C, et al.
Publicado: (2017)

Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial
por: Wasunna, Monique, et al.
Publicado: (2016)

Population pharmacokinetics of a combination of miltefosine and paromomycin in Eastern African children and adults with visceral leishmaniasis
por: Verrest, Luka, et al.
Publicado: (2023)

Validation of Two Rapid Diagnostic Tests for Visceral Leishmaniasis in Kenya
por: Mbui, Jane, et al.
Publicado: (2013)

Interest in paromomycin for the treatment of visceral leishmaniasis (kala-azar)
por: Wiwanitkit, Viroj
Publicado: (2012)

Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh
por: Rahman, Ridwanur, et al.
Publicado: (2017)

Blood Parasite Load as an Early Marker to Predict Treatment Response in Visceral Leishmaniasis in Eastern Africa
por: Verrest, Luka, et al.
Publicado: (2021)

Efficacy and Safety of Paromomycin for Visceral Leishmaniasis: A Systematic Review
por: Pokharel, Pashupati, et al.
Publicado: (2021)

Macrophage Activation Marker Neopterin: A Candidate Biomarker for Treatment Response and Relapse in Visceral Leishmaniasis
por: Kip, Anke E., et al.
Publicado: (2018)

Visceral leishmaniasis-hepatitis B/C coinfections: a rising necessity to triage patients for treatment
por: Adam, Abubakr O. A., et al.
Publicado: (2014)

Phase 4 Pharmacovigilance Trial of Paromomycin Injection for the Treatment of Visceral Leishmaniasis in India
por: Sinha, Prabhat K., et al.
Publicado: (2011)

Epidemiology of visceral leishmaniasis among children in Gadarif hospital, eastern Sudan
por: Ahmed, Mohammed Ahmed A., et al.
Publicado: (2016)

Long term outcomes and prognostics of visceral leishmaniasis in HIV infected patients with use of pentamidine as secondary prophylaxis based on CD4 level: a prospective cohort study in Ethiopia
por: Diro, Ermias, et al.
Publicado: (2019)

Immunity to Visceral Leishmaniasis
por: Ali, Nahid, et al.
Publicado: (2012)

Effectiveness Study of Paromomycin IM Injection (PMIM) for the Treatment of Visceral Leishmaniasis (VL) in Bangladesh
por: Jamil, Kazi M., et al.
Publicado: (2015)

Post-Kala-Azar Dermal Leishmaniasis: A Paradigm of Paradoxical Immune Reconstitution Syndrome in Non-HIV/AIDS Patients
por: Khalil, Eltahir Awad Gasim, et al.
Publicado: (2013)

A randomized trial of AmBisome monotherapy and AmBisome and miltefosine combination to treat visceral leishmaniasis in HIV co-infected patients in Ethiopia
por: Diro, Ermias, et al.
Publicado: (2019)

Y Chromosome Lineage- and Village-Specific Genes on Chromosomes 1p22 and 6q27 Control Visceral Leishmaniasis in Sudan
por: Miller, E. Nancy, et al.
Publicado: (2007)

Safety and immunogenicity of ChAd63-KH vaccine in post-kala-azar dermal leishmaniasis patients in Sudan
por: Younis, Brima M., et al.
Publicado: (2021)

Topical paromomycin for New World cutaneous leishmaniasis
por: Sosa, Néstor, et al.
Publicado: (2019)

Misdiagnosis and Mistreatment of Post-Kala-Azar Dermal Leishmaniasis
por: El Hassan, Ahmed Mohamed, et al.
Publicado: (2013)

Risk Factors of Inpatients Mortality of Visceral Leishmaniasis, Khartoum State, Sudan
por: Salih, Omaima Abdel Majeed Mohamed, et al.
Publicado: (2020)

Low antileishmanial drug exposure in HIV-positive visceral leishmaniasis patients on antiretrovirals: an Ethiopian cohort study
por: Kip, Anke E, et al.
Publicado: (2021)

Visceral Leishmaniasis and HIV Coinfection: Time for Concerted Action
por: van Griensven, Johan, et al.
Publicado: (2014)

Characterizing the non-linear pharmacokinetics of miltefosine in paediatric visceral leishmaniasis patients from Eastern Africa
por: Palić, Semra, et al.
Publicado: (2020)

Cost-Effectiveness Analysis of Combination Therapies for Visceral Leishmaniasis in the Indian Subcontinent
por: Meheus, Filip, et al.
Publicado: (2010)

Efficacy and safety of a combined treatment of sodium stibogluconate at 20mg/kg/day with upper maximum daily dose limit of 850mg and Paromomycin 15mg/kg/day in HIV negative visceral leishmaniasis patients. A retrospective study, northwest Ethiopia
por: Tamiru, Aschalew, et al.
Publicado: (2021)

Visceral Leishmaniasis and HIV Coinfection in East Africa
por: Diro, Ermias, et al.
Publicado: (2014)

Visceral leishmaniasis in selected communities of Hamar and Banna-Tsamai districts in Lower Omo Valley, South West Ethiopia: Sero-epidemological and Leishmanin Skin Test Surveys
por: Bekele, Fitsum, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_j8ur4pb9l5ii8c8rldjko23d36